Evidence map›Paper›PMID 26148052›Full record

ArticlePloS one2015

Occult Hepatitis B Virus Infection in Nigerian Blood Donors and Hepatitis B Virus Transmission Risks.

Opaleye O Oluyinka, Hoang Van Tong, Sy Bui Tien, Ademola H Fagbami, Olusegun Adekanle, Olusola Ojurongbe, C-Thomas Bock, Peter G Kremsner, Thirumalaisamy P Velavan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 3 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 3 syntheses or guidelines pooled it, 90 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Occult hepatitis B infection among blood donors from Yaoundé, Cameroon.Blood transfusion = Trasfusione del sangue · 2019
    Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 4 countries.

Opaleye O OluyinkaInstitute of Tropical Medicine, University of Tübingen, Tübingen, Germany; Deparment of Medical Microbiology and Parasitology, Ladoke Akintola University of Technology, Ogbomosho, Nigeria.
Hoang Van TongInstitute of Tropical Medicine, University of Tübingen, Tübingen, Germany.
Sy Bui TienDepartment of Infectious Diseases, Robert Koch Institute, Berlin, Germany; Department of Molecular Biology, 108 Military Central Hospital, Hanoi, Vietnam.
Ademola H FagbamiDeparment of Medical Microbiology and Parasitology, Ladoke Akintola University of Technology, Ogbomosho, Nigeria.
Olusegun AdekanleObafemi Awolowo University, Ile Ife, Nigeria.
Olusola OjurongbeInstitute of Tropical Medicine, University of Tübingen, Tübingen, Germany; Deparment of Medical Microbiology and Parasitology, Ladoke Akintola University of Technology, Ogbomosho, Nigeria.
C-Thomas BockDepartment of Infectious Diseases, Robert Koch Institute, Berlin, Germany; Department of Molecular Pathology, University of Tübingen, Tübingen, Germany.
Peter G KremsnerInstitute of Tropical Medicine, University of Tübingen, Tübingen, Germany.
Thirumalaisamy P VelavanInstitute of Tropical Medicine, University of Tübingen, Tübingen, Germany; Fondation Congolaise pour la Recherche Medicale, Brazzaville, Republic of Congo.
University of Tübingen · DELadoke Akintola University of Technology · NGFondation Congolaise Pour La Recherche Médicale · CGObafemi Awolowo University · NGRobert Koch Institute · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOccult hepatitis B virus infection (OBI) characterized by the absence of detectable HBsAg remains a potential threat in blood safety. We investigated the actual prevalence, viral factors and genotype of OBI infections in Nigerian blood donors.

methodsSerum collected from two blood banks were reconfirmed as HBsAg seronegative by ELISA. Forty HBsAg positive samples were employed as controls. HBV-DNA was amplified from all donors and viral loads were determined using quantitative real-time PCR. Antibodies to the HBV core, surface and HBe antigen (anti-HBc,anti-HBs,HBeAg) were measured. The PreS/S and PreC/C regions of the HBV genome were sequenced.

resultsOf the 429 blood donors, 72(17%) were confirmed as OBI by DNA detection in different reference labs and excluded the concern of possible contamination. Of the 72 OBI samples, 48(67%) were positive for anti-HBc, 25(35%) positive for anti-HBs, and 2(3%) positive for HBeAg. Of the 72 OBI samples, 31(43%) were seropositive for either anti-HBc, anti-HBs or HBeAg, 21 (30%) positive for both anti-HBc and anti-HBs,one positive for both anti-HBc and HBeAg. None of the OBI samples were positive for all three serological markers. The viral load was <50copies/ml in the OBI samples and genotype E was predominant. The L217R polymorphism in the reverse transcriptase domain of the HBV polymerase gene was observed significantly higher in OBI compared with HBsAg positive individuals (P<0.0001).

conclusionHigh incidence of OBI is relevant in high endemic areas worldwide and is a general burden in blood safety. This study signifies the high prevalence of OBI and proposes blood donor samples in Nigeria should be pre-tested for OBI by nucleic acid testing (NAT) and/or anti-HBc prior to transfusion to minimize the HBV infection risk.

Indexed as

Transfusion ReactionAdultBlood DonorsBlood SafetyCommunicable DiseasesDNA, ViralFemaleHepatitis BHepatitis B AntibodiesHepatitis B Core AntigensHepatitis B e AntigensHepatitis B Surface AntigensHepatitis B virusHumansMaleNigeriaDNA, ViralHepatitis B AntibodiesHepatitis B Core AntigensHepatitis B e AntigensHepatitis B Surface Antigens

Identifiers

PMID26148052
PMCPMC4492924
OpenAlexW1808838603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.